




RealRate

# PHARMACEUTICAL 2017

## Paratek Pharmaceuticals Inc. Rank 197 of 292





# PHARMACEUTICAL 2017

Paratek Pharmaceuticals Inc.  
Rank 197 of 292



The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 12%, being 8.6% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	132,100
Cost of Goods Sold	0
Intangible Assets	1,844
Liabilities, Current	20,412
Liabilities, Non-Current	43,073
Other Assets	600
Other Compr. Net Income	-16
Other Expenses	2,878
Other Liabilities	655
Other Net Income	1,073
Other Revenues	29
Property and Equipment	1,188
Research and Development	83,460
Selling, General and Administrative Expense	26,400

Output Variable	Value in 1000 USD
Assets	135,732
Liabilities	64,140
Expenses	112,738
Revenues	29
Stockholders Equity	71,592
Net Income	-111,636
Comprehensive Net Income	-111,644
Economic Capital Ratio	12%